u/ConclusionInfinite95 heavy metabolic stack: Reta + Tesamorelin + MOTS-c + SS-31 + KLOW
Is this peptide stack a biological masterpiece or just expensive overkill? (Reta + Tesa + MOTS-c + SS-31 + KLOW) Looking for some feedback on a heavy peptide stack I'm planning. On paper, the pathways don't explicitly clash or cancel each other out, but the sheer volume of signals makes me wonder if I'm hitting a point of diminishing returns, or worse, just stressing my system unnecessarily. Retatrutide: 1.5mg weekly KLOW Blend: 4mg daily Tesamorelin 2mg daily SS-31: 3mg daily MOTS-C: 4mg on 3 workout days a week My concerns: Both Retatrutide (via glucagon) and Tesamorelin are incredibly potent at melting visceral fat. Am I just wasting money running them concurrently, or is there a genuine synergistic effect here? Reta already bumps up resting heart rate for a lot of people. Throwing MOTS-c (which mimics high-intensity exercise signalling) on top of it feels like I might be putting my cardiovascular system under a lot of alarm. Tesamorelin can mess with insulin sensitivity and raise fasting glucose. Reta and MOTS-c usually lower it. Appreciate any insight, especially from anyone who has tracked bloodwork on a similar protocol.
The author asks the three questions that actually matter and most peptide-stack posts don't. Are Reta and Tesa redundant on visceral fat? Does MOTS-c on top of Reta's HR bump push cardio too far? Does Tesa-driven insulin resistance get hidden by Reta and MOTS-c's opposing glucose effects? Real, sharp concerns. The stack is mechanistically coherent: Tesa at the exact FDA-approved Egrifta dose, KLOW at 4mg/day (high end), MOTS-c pre-workout at high but defensible volume. Reta sourcing remains the structural risk.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | 78 | C+ | 15% | SS-31 mitochondrial-targeted antioxidant and MOTS-c AMPK activation are both legitimately longevity-relevant mechanisms; the stack isn't longevity-framed but the mitochondrial axis is doing real work. |
| Cognition | — | Not targeted | — | No ingredient with a primary cognitive mechanism. |
| Sleep & recovery | 78 | C+ | 20% | KLOW recovery cocktail at high dose plus Tesamorelin GH-axis effects on sleep architecture cover this axis indirectly; not the headline goal. |
| Energy & metabolism | 84 | B | 30% | Five compounds touching metabolic pathways (Reta triple agonism, Tesa GH-mediated lipolysis, MOTS-c AMPK, SS-31 mitochondrial). The author's question about insulin-sensitivity tension is real but unresolved without measurement. |
| Body recomposition | 84 | B | 35% | Reta + Tesa is the most-direct visceral fat combination available; KLOW for recovery; MOTS-c for exercise-aligned metabolic effect. Mechanistically coherent body-recomp protocol. |
Ingredients (5)
Retatrutide
Retatrutide on peptidelist.org ↗
- Dose
- 1.5mg weekly · weekly
- Mechanism
- GLP-1 / GIP / glucagon triple-receptor agonist. Eli Lilly trial drug; Phase 2 data exceeded tirzepatide and semaglutide on bodyweight outcomes. Glucagon agonism specifically targets visceral fat via hepatic lipolysis.
- Take
- 1.5mg/wk is below the Phase 2 trial starting dose (2mg). Conservative for a 'heavy stack' framing, which is consistent with the author's experimental epistemics. Standard retatrutide caveat applies: Phase 3 trial-stage drug, no legitimate civilian supply chain, anything from a research-peptide vendor is gray-market trial diversion or unverifiable counterfeit. The low dose softens the sourcing risk somewhat (less product, less exposure to counterfeit issues) but doesn't change the structural problem.
KLOW blend
- Dose
- 4mg daily · daily
- Mechanism
- Community-recognized peptide blend containing BPC-157, TB-500, GHK-Cu, and KPV in a fixed ratio. Marketed for recovery and tissue repair.
- Take
- 4mg/day is at the high end of typical KLOW use (most users run 1-3mg/day). Split roughly evenly across BPC-157, TB-500, GHK-Cu, and KPV, that's ~1mg of each daily, which is at or above the upper end for several components (especially TB-500, typically loaded weekly not daily). High end but recognized blend composition.
Tesamorelin
- Dose
- 2mg daily · daily
- Mechanism
- GHRH analog that drives endogenous GH release. FDA-approved as Egrifta (1mg twice daily, or 2mg once daily formulations) for HIV-associated visceral lipodystrophy. Mechanism is GH-mediated visceral fat reduction via lipolysis.
- Take
- 2mg/day is the exact FDA-approved Egrifta dose for HIV-associated lipodystrophy. Rare dose-disclosure precision for this site. Author is using it off-label for general visceral fat reduction, which is the mechanistically-coherent application but not the on-label indication. Sourcing matters: Egrifta retail is $3000+/mo; compounded tesamorelin is $200-400/mo; research-vendor lyophilized is $100-200/mo (with the usual sourcing concerns). Tesa reliably increases IGF-1 and impairs glucose tolerance at this dose, which is the basis for the author's insulin-sensitivity concern.
SS-31 (Elamipretide)
- Dose
- 3mg daily · daily
- Mechanism
- Synthetic tetrapeptide (D-Arg-2'6'-Dmt-Lys-Phe-NH2) that selectively targets inner mitochondrial membrane, binds cardiolipin, and reduces ROS production. Investigational compound; orphan-drug designation for primary mitochondrial diseases.
- Take
- SS-31 is at the upper end of typical research-vendor use (1-3mg/day subQ). The compound has been in clinical trials for primary mitochondrial myopathy, Barth syndrome, and age-related macular degeneration; orphan-drug designation for some indications. Phase trial doses have ranged 4-40mg/day depending on indication. Human evidence in healthy adults using it for general 'mitochondrial support' is essentially absent.
MOTS-c
- Dose
- 4mg, 3x/week pre-workout · workout days, pre-exercise
- Mechanism
- Mitochondrial-derived 16-amino-acid peptide encoded by mitochondrial DNA. AMPK activator with metabolic effects on insulin sensitivity, glucose homeostasis, and exercise capacity in animal and small human studies.
- Take
- 12mg/week total is at the upper end of typical research-vendor protocols (5-10mg/week is more common). Pre-workout timing aligns with MOTS-c's AMPK-activating mechanism, which is most relevant during exercise. The combination of high weekly volume with workout-day-only dosing is reasonable; the author isn't running it daily, which limits sustained AMPK activation.
Risks & interactions
- Retatrutide has no legitimate civilian supply chainhigh
Phase 3 trial-stage drug, not FDA-approved. Anything sold as 'retatrutide' on the research-peptide market is gray-market trial diversion or unverifiable counterfeit synthesis. The 1.5mg/wk dose limits total exposure but doesn't change the sourcing math.
- Reta + Tesa visceral-fat redundancy is real and unresolvedmedium
Author's question 1. Both compounds reduce visceral fat through different mechanisms (Reta via glucagon-mediated hepatic lipolysis + appetite suppression; Tesa via GH-mediated lipolysis). Theoretically additive but human combinatorial data is zero. Could be genuinely additive, could plateau due to shared downstream lipolysis pathway. Without DEXA or MRI visceral fat tracking, the author won't know which compound is contributing what.
- Cardiovascular load of Reta + MOTS-c combinationmedium
Author's question 2. Retatrutide reliably increases resting HR by 5-10 bpm (consistent across Phase 2 trial arms). MOTS-c at typical doses doesn't drive significant HR changes, but it's mimicking exercise signaling at the cellular level. The combined effect in untrained individuals could meaningfully elevate cardiovascular stress. Track resting HR and blood pressure trends weekly.
- Tesa-induced insulin resistance may be masked by Reta + MOTS-cmedium
Author's question 3. Tesamorelin at 2mg/day reliably impairs glucose tolerance (well-documented in Egrifta trials, ~10% increase in fasting glucose and 0.2-0.3 HbA1c bump). Reta and MOTS-c push glucose down. Net effect on a single fasting-glucose reading is unpredictable; HbA1c lags by 3 months. The author could be running Tesa-driven prediabetic glucose excursions invisibly if only checking fasting glucose.
- KLOW at 4mg/day is at the high endmedium
Most KLOW users run 1-3mg/day. 4mg/day distributes roughly 1mg each of BPC-157, TB-500, GHK-Cu, and KPV daily. TB-500 in particular is typically loaded weekly rather than dosed daily; sustained daily TB-500 at ~1mg is well above the standard 2-5mg weekly loading.
- SS-31 evidence base in healthy adults is sparselow
Most human SS-31 data is in primary mitochondrial disease, age-related macular degeneration, or Barth syndrome — populations with documented mitochondrial dysfunction. Use in healthy adults for general 'mitochondrial support' is essentially uncharted; the safety profile at sustained 3mg/day subQ in healthy adults isn't characterized.
The author's own question 3 — does Tesa-driven insulin resistance get hidden by Reta and MOTS-c's opposing glucose effects? — is precisely what a CGM resolves. Fasting glucose is misleading when multiple compounds push the marker in opposite directions; HbA1c lags by 3 months. A CGM gives 24/7 visibility into postprandial spikes, overnight glucose, and actual time-in-range during the protocol. Dexcom G7 or the new OTC Stelo runs $100-150/month, much cheaper than discovering the issue at the 3-month HbA1c.
Estimated cost
Retatrutide at 1.5mg/wk via research-vendor sourcing ~$150-300/mo. KLOW at 4mg/day ~$120-200/mo at research-vendor pricing (high dose drives higher cost). Tesamorelin is the wide variable: Egrifta retail ~$3000+/mo, compounded ~$200-400/mo, research-vendor lyophilized ~$100-200/mo. SS-31 3mg/day at research-vendor pricing ~$150-300/mo. MOTS-c 12mg/wk ~$100-150/mo. Range assumes compounded or research-vendor sourcing throughout.